 DNA sequences comprising dystrophin minigenes and methods of use thereof |
| The present invention provides dystrophin minigenes that are significantly reduced in size without ... |
|
| Pharmaceutical composition and method for hypermetabolic weight loss |
| The present invention relates to a device, pharmaceutical composition and method for metabolizing ... |
|
| Method for manufacturing glycoproteins having human-type glycosylation |
| What is claimed is: 1. A method of manufacturing a glycoprotein having a sugar chain, comprising a ... |
|
| Dimeric fluorescent energy transfer dyes comprising asymmetric cyanine azole-indolenine chromophores |
| What is claimed is: 1. A compound of the formula: ##STR2## wherein: a is from 0 to 6,: b is from 0 ... |
|
| Nucleic acid analogue induced transcription of double stranded DNA |
| We claim: 1. A method of transcribing RNA, using a double-stranded DNA as a template, comprising: (... |
|
| Peptide nucleic acid combinatorial libraries |
| OF THE INVENTION The synthesis of peptide nucleic acids (also known as PNA) via preformed monomers ... |
|
| Nucleic acid-containing polymerizable complex |
| OF THE INVENTION The present invention is based on the development of a polymerizable complex ... |
|
| Chiral peptide nucleic acids and methods for preparing same |
| OF THE INVENTION Specific sequence recognition of DNA or RNA is of increasing importance for the ... |
|
|
Anti-viral guanosine-rich oligonucleotides
| Details |
Inventors: Rando, Robert F.; Fennewald, Susan; Zendegui, Joseph G.; Ojwang, Joshua O.;
Assignee: Aronex Pharmaceuticals, Inc. (The Woodlands, TX)
Primary Examiner: Campell; Bruce R.
Assistant Examiner:
Attorney, Agent or Firm: McDaniel; C. Steven Conley, Rose & Tayon, P.C.
A method and compositions for treating viral infection in vitro and in vivo using a guanosine-rich oligonucleotides. The oligonucleotides are composed of at least about 50% guanosine nucleotides. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity. |
|
DETAILED DESCRIPTION In one embodiment of the present invention, there is provided a method of treating a pathophysiological state caused by a virus, comprising the step of administering a pharmacological dose of an oligonucleotide, said dose being sufficient to inhibit production of said virus, wherein said oligonucleotide contains a high percentage of guanosine bases.
In another embodiment of the present invention, there is provided a method of treating a pathophysiological state caused by a herpes simplex virus, comprising the step of administering a pharmacological dose of an oligonucleotide, said dose being sufficient to inhibit the replication of said virus, wherein said oligonucleotide contains a high percentage of guanosine bases.
In yet another embodiment of the present invention, there is provided a method of treating a pathophysiological state caused by human immunodeficiency viruses, comprising the step of administering a pharmacological dose of an oligonucleotide, said dose being sufficient to inhibit the replication of said virus, wherein said oligonucleotide contains a high percentage of guanosine bases.
In still yet another embodiment of the present invention, there is provided a method of treating a pathophysiological state caused by human papilloma virus, comprising the step of administering a pharmacological dose of an oligonucleotide, said dose being sufficient to inhibit the replication of said virus, wherein said oligonucleotide contains a high percentage of guanosine bases.
In still yet another embodiment of the present invention, there is provided a method of treating a pathophysiological state caused by human cytomegalovirus, comprising the step of administering a pharmacological dose of an oligonucleotide, said dose being sufficient to inhibit the replication of said virus, wherein said oligonucleotide contains a high percentage of guanosine bases.
In still yet another embodiment of the present invention, there is provided a method of treating a pathophysiological state caused by adenovirus, comprising the step of administering a pharmacological dose of a oligonucleotide, said dose being sufficient to inhibit the replication of said virus, wherein said oligonucleotide contains a high percentage of guanosine bases
|
| Related patents |
|
|
Nucleic acid diagnostics based on mass spectrometry or mass separation and base specific cleavage
OF THE PREFERRED EMBODIMENTS The present invention is predicated in part on a base specific cleavage reaction to generate a set of small oligonucleotides bounded by the ...
|
|
|
Polymer microparticles for drug delivery
OF THE INVENTION The term microparticle is used herein to include nanoparticles. The microparticles preferably have a size in the range 10 nm to 200.mu.m. The water-...
|
|
|
Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
The present invention provides bioactive agents encapsulated in a rapidly releasing polymeric composition capable of inducing or potentiating an immune response and ...
|
|
|
Disaccharide derivatives for treating hyperglycaemia
The invention claimed is: 1. A drug composition comprising an active ingredient and a carrier in which said active ingredient is an amide or alkyl ester of an oxidized ...
|
|
|
Gene expression profiles in liver cancer
1. A method of diagnosing hepatocellular carcinoma in a human patient, compnsing: (a) detecting the level of expression in a tissue sample of ten or more genes from T...
|
|
|
Endovascular cardiac venting catheter and method
The present invention is directed to an endovascular approach for preparing a patient's heart for cardiac procedures which does not require a grossly invasive ...
|
|
|
Bone morphogenic protein-5(BMP-5) and DNA encoding same
OF THE INVENTION Purified human BMP-5 proteins are produced by culturung a host cell transformed with the DNA sequence of Table III. The expressed BMP-5 proteins are ...
|
|
|
Adipocyte-specific protein homologs
Within one aspect of the invention is provided an isolated polypeptide comprising a sequence of amino acid residues that is at least 80% identical to SEQ ID NO:2, ...
|
|
|
LSR receptor, activity, cloning, and uses for diagnosing, preventing and/or treating obesity and related risks or complications
The LSR receptor The invention relates to a purified LSR receptor (<<Lipolysis Stimulated Receptor>>), preferably hepatic, consisting of at least one .alpha....
|
|
|
Multi-functional chimeric hematopoietic receptor agonists
1. A hematopoietic protein comprising; an amino acid sequence of the formula: Met-1 R1-L1-R2, Met-2 Ala-1 P1-L1-R2, Ala-1 R1-L1-R2, R1-L1-R2, Met-1 R2-L1-R1, Met-2 Ala-1 ...
|
|
|
Gene Therapy 
